TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07765446: Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel

Sponsor: Sironax USA, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$1,247,400

Rescue Site Savings

+$831,600

Unlock Full NCT07765446 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07765446 Rescue Dossier →